FY2026 Earnings Estimate for Cryoport Issued By Roth Capital

Cryoport, Inc. (NASDAQ:CYRX) – Equities research analysts at Roth Capital issued their FY2026 earnings estimates for shares of Cryoport in a report issued on Wednesday, March 5th. Roth Capital analyst R. Baldry forecasts that the company will post earnings of ($1.23) per share for the year. The consensus estimate for Cryoport’s current full-year earnings is ($0.99) per share.

Cryoport (NASDAQ:CYRX) last issued its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The business had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same period in the prior year, the business earned ($0.29) EPS.

Other equities research analysts have also recently issued reports about the company. Guggenheim started coverage on Cryoport in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price on the stock. Roth Mkm dropped their price objective on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Cryoport in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.29.

Cryoport Trading Up 0.8 %

Shares of NASDAQ CYRX opened at $6.66 on Thursday. Cryoport has a 12-month low of $4.58 and a 12-month high of $20.10. The company has a market cap of $329.21 million, a price-to-earnings ratio of -1.97 and a beta of 1.59. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The stock’s 50 day simple moving average is $7.31 and its 200 day simple moving average is $7.62.

Hedge Funds Weigh In On Cryoport

Several hedge funds have recently modified their holdings of the company. Thematics Asset Management lifted its stake in Cryoport by 176.2% during the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock valued at $13,828,000 after buying an additional 1,087,800 shares in the last quarter. Fred Alger Management LLC lifted its stake in Cryoport by 49.9% in the 3rd quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock worth $21,887,000 after acquiring an additional 898,481 shares in the last quarter. Cadian Capital Management LP boosted its position in Cryoport by 14.1% during the 4th quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company’s stock worth $38,332,000 after acquiring an additional 609,021 shares during the period. Point72 Asset Management L.P. purchased a new position in Cryoport during the 3rd quarter valued at about $3,405,000. Finally, Millennium Management LLC increased its holdings in shares of Cryoport by 11.0% in the 4th quarter. Millennium Management LLC now owns 4,139,869 shares of the company’s stock valued at $32,208,000 after purchasing an additional 409,353 shares during the period. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.